We have tracked every investment across both public and private psychedelics companies for the past seven years. Each year, we provide a review of the previous year’s psychedelics fundraising activity and public markets. Here’s how 2023 looked…
Members of ECNP, including EMA’s CMO, discuss the knowledge gaps they believe must be resolved in order to enable the successful implementation of psychedelic drugs as medicines.
Josh looks back at 2023 in psychedelics: from Prince Harry’s ayahuasca confessions in January through to the first submission of a psychedelic therapy for FDA approval in December.
MindMed Scraps LSD Microdosing Program • Eagerly Anticipated Ibogaine Study Publishes • Compass Pathways Announces 3-Year Research Collaboration with Interventional Psychiatry Chain, Greenbrook TMS • Gilgamesh’s GM-1020 Shows Antidepressant-Like Activity in Mice • Cybin Shares Topline Data Suggesting Deuterated DMT Candidates Can Be Bridged; IM Route Possible • atai Shares Morsel of EMP-01 Data in Phase I Readout • VA Vows to Fund Psychedelic Research • DEA Establishes Initial 2024 Aggregate Production Quotas for Psychedelics • and more…
To kick off our 2023 Year in Review, Josh looks back at some of our top articles and coverage from the year.